SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire ...
On Monday, Illumina, Inc. (NASDAQ:ILMN) agreed to acquire Standard BioTools’ (NASDAQ:LAB) subsidiary, SomaLogic. Following the announcement of the acquisition, Standard BioTools’ stock experienced a ...
Illumina announced today it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, for up to $425 ...
Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. The deal with ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, ...
Illumina, Inc. ILMN recently entered into a definitive agreement with Standard BioTools LAB to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets. The ...
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed ...
Illumina, Inc. ILMN recently announced the launch of Illumina Protein Prep, an assay designed to deliver superior performance for next-generation sequencing (NGS)-based proteomics discovery at scale.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback